English  |  正體中文  |  简体中文  |  总笔数 :0  
造访人次 :  51500508    在线人数 :  764
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"felip"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 1-6 / 6 (共1页)
1 
每页显示[10|25|50]项目

机构 日期 题名 作者
國立成功大學 2024-10 Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA Nguyen;D;Besse;B;Cho;B, C.;Lee;S, -H.;Lee;K, H.;Lu;S;Cheng;Y;Yao;Y;Girard;N;Lin;C, -C.;Felip;E;Aguilar;A;Charoentum;C;Cruz;F, J. S. M.;Majem;M;Lim;C, S.;Akamatsu;H;Hayashi;H;Yang;J, C. -H.;Kowalyszyn;R;Tiscoski;K;Franke;F;Ponomarenko;D;Arslan;C;Forster;M;Urban;D;Misch;D;Delmonte;A;Montes;L, V. G.;Gadgeel;S, M.;Cruz-Correa;M;Peguero;J;Rousey;S;Gaffar;Y;Owen;S;Schuchard;J;Diels;J;Sermon;J;Sun;T;Ennis;M;Fennema;E;Daksh;M;Sethi;S;Bauml;J, M.;Campelo, Garcia;M, R.
國立成功大學 2024-09 Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours Besse;B;Drilon;A, E.;Cho;B, C.;Camidge;D, R.;Neal;J;Lin;C-C;Liu;S, V.;Nagasaka;M;Kao;C-H, S.;Felip;E;Wekken, Van der;A, J.;Lin;C, C. C.;Bauman;J, R.;Gadgeel;S;Samant;M;Shen;J;Sun;Y;Zhu;V, W.;Upadhyay;V, A.;Lin;J, J. J.
國立成功大學 2024-06-1 Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02 Levy;Philip, Benjamin;Paz-Ares;Luis, G.;Su;Wu-Chou;Herbert;Scott, M.;Yang;Tsung-Ying;Tolcher;Anthony, W.;Lou;Yanyan;Zenke;Yoshitaka;Cortinovis;Luigi, Diego;Felip;Enriqueta;Domine;Manuel;Sr;Leventakos;Konstantinos;Calvo;Emiliano;Horiike;Atsushi;Pan;Edward;Lin;Daisy;Jia;Xiaoyu;Basak;Priyanka;Chisamore;Jon, Michael;Goto;Yasushi
國立成功大學 2024-06-1 Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05 Lisberg;Aaron;Ahn;Myung-Ju;Kitazono;Satoru;Cho;Chul, Byoung;Blumenschein;George, R.;Shum;Elaine;Pons-Tostivint;Elvire;Goto;Yasushi;Yoh;Kiyotaka;Paz-Ares;Luis, G.;Heist;Suk, Rebecca;Baas;Paul;Planchard;David;Perol;Maurice;Felip;Enriqueta;Su;Wu-Chou;Zebger-Gong;Hong;Lan;Lan;Liu;Chelsea;Sands;Jacob
國立成功大學 2024-05 Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC Yu;H, A.;Baik;C;Kim;D, -W.;Johnson;M, L.;Hayashi;H;Nishio;M;Yang;J, C. -H.;Su;W, -C.;Gold;K, A.;Koczywas;M;Smit;E, F.;Steuer;C, E.;Felip;E;Murakami;H;Kim;S, -W.;Su;X;Sato;S;Fan;P, -D.;Fujimura;M;Tanaka;Y;Patel;P;Sternberg;D, W.;Sellami;D;Jaenne;P, A.
國立成功大學 2024-02 TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) Atmaca;Akin;Paz-Ares;Luis;Ahn;Myung-Ju;Lisberg;Aaron;Kitazono;Satoru;Cho;Chul, Byoung;Blumenschein;George;Jr;Shum;Elaine;Tostivint;Pons, Elvire;Goto;Yasushi;Yoh;Kiyotaka;Heist;Rebecca;Baas;Paul;Planchard;David;Perol;Maurice;Felip;Enriqueta;Su;Wu-Chou;Zebger-Gong;Hong;Lan;Lan;Liu;Chelsea;Sands;Jacob;Reinmuth;Niels

显示项目 1-6 / 6 (共1页)
1 
每页显示[10|25|50]项目